|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bunney TD and Katan M: Phosphoinositide
signalling in cancer: Beyond PI3K and PTEN. Nat Rev Cancer.
10:342–352. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Samuels Y, Diaz LA Jr, Schmidt-Kittler O,
Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C,
Kinzler KW, et al: Mutant PIK3CA promotes cell growth and invasion
of human cancer cells. Cancer Cell. 7:561–573. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen C, Wang X, Xiong X, Liu Q, Huang Y,
Xu Q, Hu J, Ge G and Ling K: Targeting type Iγ phosphatidylinositol
phosphate kinase inhibits breast cancer metastasis. Oncogene.
34:4635–4646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Toker A: Phosphoinositides and signal
transduction. Cell Mol Life Sci. 59:761–779. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thapa N and Anderson RA: PIP2 signaling,
an integrator of cell polarity and vesicle trafficking in
directionally migrating cells. Cell Adhes Migr. 6:409–412. 2012.
View Article : Google Scholar
|
|
10
|
Ling K, Schill NJ, Wagoner MP, Sun Y and
Anderson RA: Movin' on up: The role of PtdIns(4,5)P(2) in cell
migration. Trends Cell Biol. 16:276–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun Y, Turbin DA, Ling K, Thapa N, Leung
S, Huntsman DG and Anderson RA: Type I gamma phosphatidylinositol
phosphate kinase modulates invasion and proliferation and its
expression correlates with poor prognosis in breast cancer. Breast
Cancer Res. 12:R62010. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Silver DL, Naora H, Liu J, Cheng W and
Montell DJ: Activated signal transducer and activator of
transcription (STAT) 3: Localization in focal adhesions and
function in ovarian cancer cell motility. Cancer Res. 64:3550–3558.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du Y, Feng J, Wang R, Zhang H and Liu J:
Effects of flavonoids from Potamogeton crispus L on proliferation,
migration, and invasion of human ovarian cancer cells. PLoS One.
10:e01306852015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miller CR, Oliver KE and Farley JH: MEK1/2
inhibitors in the treatment of gynecologic malignancies. Gynecol
Oncol. 133:128–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fresno Vara JA, Casado E, De Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Al-Alem L and Curry TE Jr: Ovarian cancer:
Involvement of the matrix metalloproteinases. Reproduction.
150:R55–R64. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Davidson B, Goldberg I, Gotlieb WH,
Kopolovic J, Ben-Baruch G, Nesland JM and Reich R: The prognostic
value of metalloproteinases and angiogenic factors in ovarian
carcinoma. Mol Cell Endocrinol. 187:39–45. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grandis JR, Drenning SD, Chakraborty A,
Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but
not Stat1 activation for epidermal growth factor receptor- mediated
cell growth In vitro. J Clin Invest. 102:1385–1392. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnston PA and Grandis JR: STAT3
signaling: Anticancer strategies and challenges. Mol Interv.
11:18–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saini U, Naidu S, ElNaggar AC, Bid HK,
Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P,
et al: Elevated STAT3 expression in ovarian cancer ascites promotes
invasion and metastasis: A potential therapeutic target. Oncogene.
36:168–181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang D, Li C, Zhang Y, Wang M, Jiang N,
Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, et al: Combined
inhibition of PI3K and PARP is effective in the treatment of
ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol.
142:548–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Banerjee S and Kaye SB: New strategies in
the treatment of ovarian cancer: Current clinical perspectives and
future potential. Clin Cancer Res. 19:961–968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carden CP, Stewart A, Thavasu P, Kipps E,
Pope L, Crespo M, Miranda S, Attard G, Garrett MD, Clarke PA, et
al: The association of PI3 kinase signaling and chemoresistance in
advanced ovarian cancer. Mol Cancer Ther. 11:1609–1617. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wood LD, Parsons DW, Jones S, Lin J,
Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The
genomic landscapes of human breast and colorectal cancers. Science.
318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomas RK, Baker AC, Debiasi RM, Winckler
W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L,
et al: High-throughput oncogene mutation profiling in human cancer.
Nat Genet. 39:347–351. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Samuels Y, Wang Z, Bardelli A, Silliman N,
Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al:
High frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:554. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee
SH, Zhang J, Signoretti S, Loda M, Roberts TM, et al: Essential
roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis.
Nature. 454:776–779. 2008.PubMed/NCBI
|
|
33
|
Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup
OV, Mikami A and Roberts TM: The p110α isoform of PI3K is essential
for proper growth factor signaling and oncogenic transformation.
Proc Natl Acad Sci USA. 103:16296–16300. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ciraolo E, Iezzi M, Marone R, Marengo S,
Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, et al:
Phosphoinositide 3-kinase p110β activity: Key role in metabolism
and mammary gland cancer but not development. Sci Signal.
1:ra32008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guillermet-Guibert J, Bjorklof K, Salpekar
A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K
and Vanhaesebroeck B: The p110β isoform of phosphoinositide
3-kinase signals downstream of G protein-coupled receptors and is
functionally redundant with p110γ. Proc Natl Acad Sci USA.
105:8292–8297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Graupera M, Guillermet-Guibert J, Foukas
LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J,
Cutillas PR, et al: Angiogenesis selectively requires the p110α
isoform of PI3K to control endothelial cell migration. Nature.
453:662–666. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jun T, Gjoerup O and Roberts TM: Tangled
webs: Evidence of cross-talk between c-Raf-1 and Akt. Sci STKE.
1999:PE11999.PubMed/NCBI
|
|
38
|
Zhang J, Yang PL and Gray NS: Targeting
cancer with small molecule kinase inhibitors. Nat Rev Cancer.
9:28–39. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Di Paolo G, Pellegrini L, Letinic K,
Cestra G, Zoncu R, Voronov S, Chang S, Guo J, Wenk MR and De
Camilli P: Recruitment and regulation of phosphatidylinositol
phosphate kinase type 1 γ by the FERM domain of talin. Nature.
420:85–89. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ling K, Doughman RL, Firestone AJ, Bunce
MW and Anderson RA: Type I γ phosphatidylinositol phosphate kinase
targets and regulates focal adhesions. Nature. 420:89–93. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wulfkuhle JD, Aquino JA, Calvert VS,
Fishman DA, Coukos G, Liotta LA and Petricoin EF III: Signal
pathway profiling of ovarian cancer from human tissue specimens
using reverse-phase protein microarrays. Proteomics. 3:2085–2090.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Coticchia CM, Curatolo AS, Zurakowski D,
Yang J, Daniels KE, Matulonis UA and Moses MA: Urinary MMP-2 and
MMP-9 predict the presence of ovarian cancer in women with normal
CA125 levels. Gynecol Oncol. 123:295–300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chakraborti S, Mandal M, Das S, Mandal A
and Chakraborti T: Regulation of matrix metalloproteinases: An
overview. Mol Cell Biochem. 253:269–285. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Delassus GS, Cho H, Park J and Eliceiri
GL: New pathway links from cancer-progression determinants to gene
expression of matrix metalloproteinases in breast cancer cells. J
Cell Physiol. 217:739–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liotta LA, Steeg PS and Stetler-Stevenson
WG: Cancer metastasis and angiogenesis: An imbalance of positive
and negative regulation. Cell. 64:327–336. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion, metastasis, and angiogenesis.
Surg Oncol Clin N Am. 10:383–392. 2001.PubMed/NCBI
|
|
49
|
Zou M, Zhang X and Xu C: IL6-induced
metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of
3,3-diindolylmethane in ovarian cancer cells. Cell Oncol (Dordr).
39:47–57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang X, Liu P, Zhang B, Mao H, Shen L and
Ma Y: Inhibitory effects of STAT3 decoy oligodeoxynucleotides on
human epithelial ovarian cancer cell growth in vivo. Int J Mol Med.
32:623–628. 2013.PubMed/NCBI
|
|
51
|
Thapa N, Choi S, Hedman A, Tan X and
Anderson RA: Phosphatidylinositol phosphate 5-kinase Iγi2 in
association with Src controls anchorage-independent growth of tumor
cells. J Biol Chem. 288:34707–34718. 2013. View Article : Google Scholar : PubMed/NCBI
|
